nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—MARK2—salivary gland cancer	0.747	1	CbGaD
Ruxolitinib—LTK—tongue—salivary gland cancer	0.00394	0.0535	CbGeAlD
Ruxolitinib—JAK1—neck—salivary gland cancer	0.0018	0.0244	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—salivary gland cancer	0.00147	0.02	CbGeAlD
Ruxolitinib—JAK1—parotid gland—salivary gland cancer	0.00146	0.0199	CbGeAlD
Ruxolitinib—JAK1—saliva-secreting gland—salivary gland cancer	0.0014	0.019	CbGeAlD
Ruxolitinib—DAPK2—parotid gland—salivary gland cancer	0.0014	0.019	CbGeAlD
Ruxolitinib—BMP2K—neck—salivary gland cancer	0.00135	0.0183	CbGeAlD
Ruxolitinib—DAPK2—saliva-secreting gland—salivary gland cancer	0.00134	0.0182	CbGeAlD
Ruxolitinib—CLK2—parotid gland—salivary gland cancer	0.0013	0.0177	CbGeAlD
Ruxolitinib—JAK3—connective tissue—salivary gland cancer	0.0013	0.0176	CbGeAlD
Ruxolitinib—JAK1—connective tissue—salivary gland cancer	0.00129	0.0175	CbGeAlD
Ruxolitinib—CLK2—saliva-secreting gland—salivary gland cancer	0.00125	0.0169	CbGeAlD
Ruxolitinib—JAK1—epithelium—salivary gland cancer	0.00122	0.0166	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—salivary gland cancer	0.0012	0.0163	CbGeAlD
Ruxolitinib—NUAK2—parotid gland—salivary gland cancer	0.00117	0.0159	CbGeAlD
Ruxolitinib—RET—neck—salivary gland cancer	0.00114	0.0155	CbGeAlD
Ruxolitinib—NUAK2—saliva-secreting gland—salivary gland cancer	0.00112	0.0152	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—salivary gland cancer	0.00111	0.0151	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—salivary gland cancer	0.00108	0.0146	CbGeAlD
Ruxolitinib—ROCK1—epithelium—salivary gland cancer	0.00105	0.0143	CbGeAlD
Ruxolitinib—MAP3K7—parotid gland—salivary gland cancer	0.000986	0.0134	CbGeAlD
Ruxolitinib—TYK2—parotid gland—salivary gland cancer	0.000968	0.0132	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—salivary gland cancer	0.000965	0.0131	CbGeAlD
Ruxolitinib—MKNK2—parotid gland—salivary gland cancer	0.000956	0.013	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—salivary gland cancer	0.000948	0.0129	CbGeAlD
Ruxolitinib—MAP3K7—saliva-secreting gland—salivary gland cancer	0.000944	0.0128	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—salivary gland cancer	0.000942	0.0128	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—salivary gland cancer	0.000936	0.0127	CbGeAlD
Ruxolitinib—TYK2—saliva-secreting gland—salivary gland cancer	0.000927	0.0126	CbGeAlD
Ruxolitinib—MKNK2—saliva-secreting gland—salivary gland cancer	0.000915	0.0124	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—salivary gland cancer	0.000884	0.012	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—salivary gland cancer	0.00088	0.0119	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—salivary gland cancer	0.000876	0.0119	CbGeAlD
Ruxolitinib—PRKCE—lymph node—salivary gland cancer	0.000864	0.0117	CbGeAlD
Ruxolitinib—TYK2—connective tissue—salivary gland cancer	0.000852	0.0116	CbGeAlD
Ruxolitinib—MAP3K3—parotid gland—salivary gland cancer	0.000849	0.0115	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—salivary gland cancer	0.000841	0.0114	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—salivary gland cancer	0.000837	0.0114	CbGeAlD
Ruxolitinib—PLK1—lymph node—salivary gland cancer	0.00083	0.0113	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—salivary gland cancer	0.00083	0.0113	CbGeAlD
Ruxolitinib—RET—connective tissue—salivary gland cancer	0.00082	0.0111	CbGeAlD
Ruxolitinib—MAP3K3—saliva-secreting gland—salivary gland cancer	0.000813	0.011	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—salivary gland cancer	0.000811	0.011	CbGeAlD
Ruxolitinib—MKNK2—epithelium—salivary gland cancer	0.000798	0.0108	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—salivary gland cancer	0.000791	0.0107	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—salivary gland cancer	0.000788	0.0107	CbGeAlD
Ruxolitinib—RET—epithelium—salivary gland cancer	0.000779	0.0106	CbGeAlD
Ruxolitinib—JAK2—connective tissue—salivary gland cancer	0.000775	0.0105	CbGeAlD
Ruxolitinib—TAOK3—parotid gland—salivary gland cancer	0.000774	0.0105	CbGeAlD
Ruxolitinib—TAOK3—saliva-secreting gland—salivary gland cancer	0.000741	0.0101	CbGeAlD
Ruxolitinib—JAK2—epithelium—salivary gland cancer	0.000736	0.01	CbGeAlD
Ruxolitinib—PLK3—lymph node—salivary gland cancer	0.000693	0.00941	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—salivary gland cancer	0.000681	0.00925	CbGeAlD
Ruxolitinib—LTK—lymph node—salivary gland cancer	0.000669	0.00909	CbGeAlD
Ruxolitinib—CAMK1—lymph node—salivary gland cancer	0.000648	0.0088	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—salivary gland cancer	0.00064	0.0087	CbGeAlD
Ruxolitinib—MARK2—lymph node—salivary gland cancer	0.000629	0.00855	CbGeAlD
Ruxolitinib—TYK2—lymphoid tissue—salivary gland cancer	0.000623	0.00846	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—salivary gland cancer	0.000615	0.00835	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—salivary gland cancer	0.0006	0.00815	CbGeAlD
Ruxolitinib—TAOK2—lymph node—salivary gland cancer	0.000582	0.00791	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—salivary gland cancer	0.000567	0.0077	CbGeAlD
Ruxolitinib—JAK3—lymph node—salivary gland cancer	0.000535	0.00727	CbGeAlD
Ruxolitinib—DCLK1—lymph node—salivary gland cancer	0.000532	0.00722	CbGeAlD
Ruxolitinib—JAK1—lymph node—salivary gland cancer	0.000532	0.00722	CbGeAlD
Ruxolitinib—PLK4—lymph node—salivary gland cancer	0.000528	0.00718	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—salivary gland cancer	0.000519	0.00705	CbGeAlD
Ruxolitinib—PHKG2—lymph node—salivary gland cancer	0.000516	0.00701	CbGeAlD
Ruxolitinib—DAPK2—lymph node—salivary gland cancer	0.000507	0.00689	CbGeAlD
Ruxolitinib—STK16—lymph node—salivary gland cancer	0.000499	0.00678	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—salivary gland cancer	0.000498	0.00677	CbGeAlD
Ruxolitinib—HIPK2—lymph node—salivary gland cancer	0.000496	0.00674	CbGeAlD
Ruxolitinib—DAPK3—lymph node—salivary gland cancer	0.000477	0.00648	CbGeAlD
Ruxolitinib—CLK2—lymph node—salivary gland cancer	0.000472	0.00642	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—salivary gland cancer	0.000447	0.00606	CbGeAlD
Ruxolitinib—BMPR2—lymph node—salivary gland cancer	0.000445	0.00604	CbGeAlD
Ruxolitinib—NUAK2—lymph node—salivary gland cancer	0.000425	0.00577	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—salivary gland cancer	0.000398	0.00541	CbGeAlD
Ruxolitinib—BMP2K—lymph node—salivary gland cancer	0.000398	0.00541	CbGeAlD
Ruxolitinib—LRRK2—lymph node—salivary gland cancer	0.000394	0.00536	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—salivary gland cancer	0.000361	0.00491	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—salivary gland cancer	0.000358	0.00486	CbGeAlD
Ruxolitinib—TYK2—lymph node—salivary gland cancer	0.000352	0.00477	CbGeAlD
Ruxolitinib—IRAK1—lymph node—salivary gland cancer	0.000347	0.00471	CbGeAlD
Ruxolitinib—MKNK2—lymph node—salivary gland cancer	0.000347	0.00471	CbGeAlD
Ruxolitinib—RET—lymph node—salivary gland cancer	0.000338	0.0046	CbGeAlD
Ruxolitinib—JAK2—lymph node—salivary gland cancer	0.00032	0.00434	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—salivary gland cancer	0.000308	0.00419	CbGeAlD
Ruxolitinib—TAOK3—lymph node—salivary gland cancer	0.000281	0.00382	CbGeAlD
Ruxolitinib—GRK1—Disease—HRAS—salivary gland cancer	7.28e-06	4.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CREBBP—salivary gland cancer	7.21e-06	4.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAP2K2—salivary gland cancer	7.17e-06	3.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CDH1—salivary gland cancer	7.16e-06	3.99e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—PIK3CA—salivary gland cancer	7.12e-06	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—salivary gland cancer	7.11e-06	3.96e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—PTEN—salivary gland cancer	7.09e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NOTCH1—salivary gland cancer	7.08e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JAG1—salivary gland cancer	7.07e-06	3.94e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—PTEN—salivary gland cancer	7.06e-06	3.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EP300—salivary gland cancer	7.05e-06	3.93e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGFR4—salivary gland cancer	7.04e-06	3.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF16—salivary gland cancer	7.02e-06	3.91e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—PIK3CA—salivary gland cancer	7.01e-06	3.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAP2K2—salivary gland cancer	6.95e-06	3.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FBXW7—salivary gland cancer	6.93e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—PIK3CA—salivary gland cancer	6.93e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CREBBP—salivary gland cancer	6.93e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JAG1—salivary gland cancer	6.87e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGFR4—salivary gland cancer	6.84e-06	3.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EP300—salivary gland cancer	6.77e-06	3.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—HRAS—salivary gland cancer	6.76e-06	3.77e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EP300—salivary gland cancer	6.74e-06	3.75e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FBXW7—salivary gland cancer	6.73e-06	3.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—PTEN—salivary gland cancer	6.72e-06	3.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—salivary gland cancer	6.7e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JAG1—salivary gland cancer	6.66e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CREBBP—salivary gland cancer	6.66e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FOXO3—salivary gland cancer	6.65e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGFR4—salivary gland cancer	6.63e-06	3.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAP2K2—salivary gland cancer	6.62e-06	3.69e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HRAS—salivary gland cancer	6.58e-06	3.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTEN—salivary gland cancer	6.55e-06	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—HRAS—salivary gland cancer	6.54e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—PTEN—salivary gland cancer	6.53e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FBXW7—salivary gland cancer	6.53e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—PTEN—salivary gland cancer	6.5e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—HRAS—salivary gland cancer	6.43e-06	3.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CREBBP—salivary gland cancer	6.42e-06	3.58e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EP300—salivary gland cancer	6.41e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—HRAS—salivary gland cancer	6.41e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—PTEN—salivary gland cancer	6.35e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—PTEN—salivary gland cancer	6.33e-06	3.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAP2K2—salivary gland cancer	6.28e-06	3.5e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EP300—salivary gland cancer	6.25e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—PIK3CA—salivary gland cancer	6.24e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EP300—salivary gland cancer	6.23e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—PIK3CA—salivary gland cancer	6.22e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EP300—salivary gland cancer	6.2e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAP2K2—salivary gland cancer	6.17e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FOXO3—salivary gland cancer	6.14e-06	3.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—PIK3CA—salivary gland cancer	6.12e-06	3.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAML2—salivary gland cancer	6.09e-06	3.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—PTEN—salivary gland cancer	6.08e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EP300—salivary gland cancer	6.05e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EP300—salivary gland cancer	6.04e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—PIK3CA—salivary gland cancer	6.03e-06	3.36e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PTEN—salivary gland cancer	5.99e-06	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOTCH1—salivary gland cancer	5.98e-06	3.33e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—PIK3CA—salivary gland cancer	5.96e-06	3.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAP2K2—salivary gland cancer	5.94e-06	3.31e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—PIK3CA—salivary gland cancer	5.86e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FOXO3—salivary gland cancer	5.85e-06	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—salivary gland cancer	5.77e-06	3.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—salivary gland cancer	5.76e-06	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EP300—salivary gland cancer	5.71e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FOXO3—salivary gland cancer	5.68e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—salivary gland cancer	5.67e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—salivary gland cancer	5.66e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—PIK3CA—salivary gland cancer	5.51e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FOXO3—salivary gland cancer	5.5e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CREBBP—salivary gland cancer	5.48e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—PIK3CA—salivary gland cancer	5.48e-06	3.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDH1—salivary gland cancer	5.44e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAP2K2—salivary gland cancer	5.43e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—salivary gland cancer	5.42e-06	3.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOTCH1—salivary gland cancer	5.42e-06	3.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CREBBP—salivary gland cancer	5.42e-06	3.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EP300—salivary gland cancer	5.34e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—salivary gland cancer	5.33e-06	2.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CREBBP—salivary gland cancer	5.32e-06	2.97e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ISYNA1—salivary gland cancer	5.31e-06	2.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDH1—salivary gland cancer	5.28e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—EP300—salivary gland cancer	5.24e-06	2.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JAG1—salivary gland cancer	5.2e-06	2.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR4—salivary gland cancer	5.18e-06	2.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CREBBP—salivary gland cancer	5.16e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PTEN—salivary gland cancer	5.15e-06	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOTCH1—salivary gland cancer	5.14e-06	2.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDH1—salivary gland cancer	5.13e-06	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—salivary gland cancer	5.12e-06	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FBXW7—salivary gland cancer	5.1e-06	2.84e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—salivary gland cancer	5.1e-06	2.84e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—PIK3CA—salivary gland cancer	5.09e-06	2.84e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—salivary gland cancer	5.07e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOTCH1—salivary gland cancer	5.06e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAP2K2—salivary gland cancer	5.01e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—PIK3CA—salivary gland cancer	5e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—PIK3CA—salivary gland cancer	4.98e-06	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PTEN—salivary gland cancer	4.95e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CREBBP—salivary gland cancer	4.92e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EP300—salivary gland cancer	4.91e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—salivary gland cancer	4.82e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—salivary gland cancer	4.82e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAP2K2—salivary gland cancer	4.77e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTEN—salivary gland cancer	4.76e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—salivary gland cancer	4.75e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—PIK3CA—salivary gland cancer	4.74e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EP300—salivary gland cancer	4.72e-06	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CREBBP—salivary gland cancer	4.66e-06	2.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAP2K2—salivary gland cancer	4.63e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—salivary gland cancer	4.63e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—PIK3CA—salivary gland cancer	4.62e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PIK3CA—salivary gland cancer	4.62e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—salivary gland cancer	4.61e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—PIK3CA—salivary gland cancer	4.61e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PTEN—salivary gland cancer	4.59e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CREBBP—salivary gland cancer	4.59e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—PIK3CA—salivary gland cancer	4.58e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EP300—salivary gland cancer	4.53e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAP2K2—salivary gland cancer	4.49e-06	2.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—PIK3CA—salivary gland cancer	4.48e-06	2.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—PIK3CA—salivary gland cancer	4.47e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—salivary gland cancer	4.39e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—PIK3CA—salivary gland cancer	4.38e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EP300—salivary gland cancer	4.37e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MARCKS—salivary gland cancer	4.33e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—PIK3CA—salivary gland cancer	4.31e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FOXO3—salivary gland cancer	4.3e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—PIK3CA—salivary gland cancer	4.29e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—salivary gland cancer	4.28e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—salivary gland cancer	4.27e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—salivary gland cancer	4.26e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—salivary gland cancer	4.24e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PIK3CA—salivary gland cancer	4.22e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—salivary gland cancer	4.14e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—salivary gland cancer	4.13e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOTCH1—salivary gland cancer	4.11e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CREBBP—salivary gland cancer	4.03e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PYGB—salivary gland cancer	4.02e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—salivary gland cancer	4.01e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—salivary gland cancer	4.01e-06	2.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PIK3CA—salivary gland cancer	3.98e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—salivary gland cancer	3.97e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—salivary gland cancer	3.92e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—salivary gland cancer	3.91e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH1—salivary gland cancer	3.91e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—salivary gland cancer	3.91e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—salivary gland cancer	3.88e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—salivary gland cancer	3.87e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—salivary gland cancer	3.8e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH1—salivary gland cancer	3.8e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—salivary gland cancer	3.75e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—salivary gland cancer	3.74e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CREBBP—salivary gland cancer	3.73e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—salivary gland cancer	3.69e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—salivary gland cancer	3.69e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH1—salivary gland cancer	3.68e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—salivary gland cancer	3.68e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—salivary gland cancer	3.66e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—salivary gland cancer	3.63e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—salivary gland cancer	3.63e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—salivary gland cancer	3.62e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—salivary gland cancer	3.59e-06	2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CREBBP—salivary gland cancer	3.55e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—salivary gland cancer	3.52e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAP2K2—salivary gland cancer	3.51e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—salivary gland cancer	3.51e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—salivary gland cancer	3.49e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—salivary gland cancer	3.45e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CREBBP—salivary gland cancer	3.44e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—salivary gland cancer	3.39e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—salivary gland cancer	3.36e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—salivary gland cancer	3.35e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—salivary gland cancer	3.35e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CREBBP—salivary gland cancer	3.34e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—salivary gland cancer	3.33e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	3.28e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—salivary gland cancer	3.28e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—salivary gland cancer	3.24e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—salivary gland cancer	3.23e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—salivary gland cancer	3.18e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	3.16e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—salivary gland cancer	3.13e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—salivary gland cancer	3.12e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—salivary gland cancer	3.1e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—salivary gland cancer	2.99e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—salivary gland cancer	2.94e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—salivary gland cancer	2.88e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—salivary gland cancer	2.88e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	2.87e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—salivary gland cancer	2.76e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—salivary gland cancer	2.75e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—salivary gland cancer	2.73e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—salivary gland cancer	2.72e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—salivary gland cancer	2.68e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—salivary gland cancer	2.66e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—salivary gland cancer	2.64e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—salivary gland cancer	2.62e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREBBP—salivary gland cancer	2.61e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—salivary gland cancer	2.6e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—salivary gland cancer	2.56e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—salivary gland cancer	2.55e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—salivary gland cancer	2.54e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—salivary gland cancer	2.53e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—salivary gland cancer	2.53e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—salivary gland cancer	2.48e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—salivary gland cancer	2.48e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—salivary gland cancer	2.47e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—salivary gland cancer	2.46e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—salivary gland cancer	2.45e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—salivary gland cancer	2.41e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—salivary gland cancer	2.41e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—salivary gland cancer	2.38e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—salivary gland cancer	2.35e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—salivary gland cancer	2.34e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—salivary gland cancer	2.31e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—salivary gland cancer	2.29e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	2.27e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—salivary gland cancer	2.27e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—salivary gland cancer	2.27e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	2.26e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—salivary gland cancer	2.24e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—salivary gland cancer	2.22e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—salivary gland cancer	2.17e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—salivary gland cancer	2.14e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—salivary gland cancer	2.06e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—salivary gland cancer	2.03e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—salivary gland cancer	1.93e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—salivary gland cancer	1.88e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—salivary gland cancer	1.88e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—salivary gland cancer	1.86e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.79e-06	9.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—salivary gland cancer	1.78e-06	9.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—salivary gland cancer	1.74e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—salivary gland cancer	1.73e-06	9.67e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—salivary gland cancer	1.73e-06	9.63e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—salivary gland cancer	1.68e-06	9.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—salivary gland cancer	1.68e-06	9.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—salivary gland cancer	1.65e-06	9.21e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—salivary gland cancer	1.63e-06	9.07e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—salivary gland cancer	1.6e-06	8.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—salivary gland cancer	1.56e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—salivary gland cancer	1.31e-06	7.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—salivary gland cancer	1.27e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—salivary gland cancer	1.22e-06	6.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	8.82e-07	4.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	6.3e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—salivary gland cancer	6.01e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	4.44e-07	2.48e-06	CbGpPWpGaD
